E
Cardio Diagnostics Holdings, Inc. CDIO
$0.73 -$0.109-12.99%
Recommendation
Sell
Prev Close
$0.73
Volume
652,913
Avg Vol (90D)
698,935
Market Cap
$15.76M
Dividend & Yield
--
52-Week Range
$0.171 - $3.56
P/E (TTM)
--
EPS (TTM)
-$0.7363
My Lists My Alerts
Report
Rating
Reward
E
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week
5/13/2024 - Business Wire
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update
5/1/2024 - Ticker Report
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD Test Could Save Health Insurers Over $113 Million Annually
4/29/2024 - Business Wire
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
4/9/2024 - Business Wire
Cardio Diagnostics Holdings Gains After Signing Telehealth Agreement With Navierre
4/4/2024 - RTT News - Momentum Stocks
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
4/4/2024 - Business Wire
Cardio Diagnostics Unveils New Investor Engagement Materials
4/2/2024 - TipRanks Financial Blog
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiologys 73rd Annual Scientific Session
3/14/2024 - Business Wire
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease
3/5/2024 - Business Wire
Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout
2/15/2024 - Business Wire
BlackRock Acquires Stake In Cardio Diagnostics
2/8/2024 - Benzinga
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters
2/7/2024 - Business Wire
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests
2/5/2024 - Business Wire
Cardio Diagnostics Raises $1M in Private Placement
2/3/2024 - TipRanks Financial Blog
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Update
1/27/2024 - Ticker Report
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor
1/24/2024 - Business Wire
Northland Capmk Research Analysts Lift Earnings Estimates for Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO)
1/19/2024 - Ticker Report
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
1/8/2024 - Business Wire
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk
1/4/2024 - Business Wire
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
1/3/2024 - Business Wire
Why Cardio Diagnostics Holdings Stock Is Racing Higher
1/2/2024 - Benzinga
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
1/2/2024 - Business Wire
Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors
12/21/2023 - Business Wire
Cardio Diagnostics' Breakthrough Coronary Heart Disease Detection Test Published In The Journal Of The American Heart Association
12/15/2023 - Benzinga
Income Statement
Total Revenue (TTM)
$17.00K
EBITDA (TTM)
-$7.13M
EBIT (TTM)
-$7.24M
Net Income (TTM)
-$8.38M
Balance Sheet
Total Assets (Q)
$4.46M
Total Debt (Q)
$1.26M
Total Liabilities (Q)
$1.50M
Book Value Per Share (Q)
$0.144
Cash Flow
Cash from Operations (TTM)
-$5.67M
Cash from Investing (TTM)
-$794.30K
Cash from Financing (TTM)
$3.63M
Net Change in Cash (TTM)
-$2.83M
Filings
Filing Date
Monday, April 1, 2024
Period Date
Sunday, December 31, 2023
Next Filing
Week of May 13 and 17 (est)
Price History
Loading...
Beta
0.13
7-Day Total Return
0.33%
30-Day Total Return
-34.23%
60-Day Total Return
-59.67%
90-Day Total Return
-75.17%
Year to Date Total Return
-76.14%
1-Year Total Return
-50.00%
2-Year Total Return
-92.63%
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Oct 26, 2023 - $0.171
52-week High
Jan 02, 2024 - $3.56
Valuation
Market Cap
$15.76M - Nano Cap
Enterprise Value
$15.26M
Price/Sales (TTM)
912.50
Price/Book (Q)
5.07
Dividends and Shares
Shares Outstanding
19.02M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
cardiodiagnosticsinc.com
Phone Number
302 281 2147
Address
311 West Superior Street
Chicago, IL 60654
Country
United States
Year Founded
2017
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease... more
NASDAQ 05/17/2024 4:00PM Eastern Quotes delayed
Weiss Ratings